Premium
Anti‐polymorphonuclear neutrophil antibodies in patients with leukopenia or neutropenia
Author(s) -
RIERA N. E.,
ROSSO SALTÓ M.,
GALÁN V.,
CANALEJO K.,
KHOURY M.,
AIXALÁ M.,
KANTOR G. L.,
VERMEULEN M.,
BENGIÓ R.,
DE BRACCO M. M. E.
Publication year - 2010
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2009.01173.x
Subject(s) - antibody , cd16 , granulocyte , leukopenia , neutropenia , immunology , immune system , flow cytometry , medicine , immunofluorescence , tumor necrosis factor alpha , chemotherapy , cd3 , cd8
Summary Introduction: Immune humoral neutropenia (Np) could be the consequence of anti‐polymorphonuclear neutrophil (PMN) antibodies, circulating immune complexes (CIC) and/or antibodies against myeloid precursors. Granulocyte immunofluorescence test (GIFT) and a leukoagglutination technique (LAGT) assays are recommended for its diagnosis. Methods: Fifty adult patients with secondary Np were screened for anti‐PMN. GIFT by flow cytometry from viable PMN and LAGT were employed. In addition, CIC levels, low expression of CD16 b (CD16 b low ), PMN phenotype and sera tumor necrosis factor‐alpha (TNF‐α) were also evaluated. Results: Direct IgG‐PMN binding (dir‐GIFT) was positive in 16% of the patients. Antibodies against autologous PMN were detected in 32% of the samples by indirect (ind)‐GIFT and demonstrated in 70% of the sera by both ind‐GIFT and/or LAGT. Predominance of human neutrophil alloantigen (HNA)‐1b and HNA‐2 expression was confirmed. CD16 b low was detected in 16% of the patient’s PMN and TNF‐α in 68% of sera patients. Conclusion: Our results suggest that diagnosis of immune Np in the laboratory may be improved by focusing on patient’s PMN together with the assessment of cellular markers.